Akari Therapeutics (AKTX) is having a good Thursday. The oncology biotech company's shares surged 3.17% to $3.23 as investors cheered two things: an upcoming earnings report and a shiny new patent from Europe.

Let's start with the numbers. Akari will report its first-quarter 2026 earnings on May 26. Analysts are expecting a loss of $2.80 per share. That might sound rough, but the company has beaten earnings estimates for three straight quarters, so there's some optimism in the air. Investors are hoping for another beat.

Then there's the patent news. On Tuesday, Akari announced that the European Patent Office granted it a composition-of-matter patent for its PH1 ADC payload platform. This isn't a small deal — the patent covers more than 35 countries, including Germany, France, and the U.K. It's a big stamp of approval for the company's technology.

CEO Abizer Gaslightwala put it this way: "This European patent grant further strengthens the foundation of our proprietary payload platform and reinforces our ability to build a differentiated ADC pipeline."

So what exactly is this platform? Akari's technology focuses on RNA splicing biology — basically, it tries to mess with how cancer cells process their genetic instructions, disrupting their growth and waking up the immune system. The company has two lead candidates: AKTX-101, which is in IND-enabling studies, and AKTX-102. A Phase 1 human trial for AKTX-101 is expected by mid-2027.

The European patent follows a similar approval in Australia last month. Akari now also holds patents in the U.S., China, Japan, and India. That's a pretty global IP portfolio for a company with a market cap that's been battered.

And that brings us to the stock's technical picture. It's not pretty. Akari shares are down 94.17% over the past 12 months and are trading near the bottom of their 52-week range — the low is $3.02, the high is $56.80. The stock is well below its major moving averages: the 20-day simple moving average (SMA) sits at $5.47, and the 200-day SMA is at $19.20. Those levels act like gravity, pulling any rallies back down. The moving averages are also in a classic bearish alignment — the 20-day is below the 50-day, which is below the 200-day. That usually means any bounce is likely to be short-lived.

Key resistance to watch: $5.47 (the 20-day SMA). Key support: $3.02 (the 52-week low). With the stock at $3.23, it's not far from that floor.

So, is this a turnaround story or a dead cat bounce? The patent news and earnings beat streak are real positives, but the chart is screaming caution. For now, investors are betting on the science and the IP — and hoping the numbers follow.